NLRP3 and atherosclerosis: In contrast to complete inhibition of the NLRP3 inflammasome or its products, precise, selective inhibition of dyslipidemia-driven inflammasome activation in atherosclerosis may be less immunosuppressive, and, thus, clinically more acceptable as a therapeutic strategy to reduce CVD risk.